2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

628. Aggressive Lymphomas: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

1923 Impact of bendamustine versus fludarabine-cyclophosphamide lymphodepletion on outcomes after CD19 CAR T-cell therapy for large B-cell lymphoma

Muhammad Kashif Amin, MD, MSc, FACP, Rubbia Sabir2, Saad Abdul Kareem, MD3, Nabeeha Noor4, Shah Rukh5, Mehdi Hamadani, MD6, Joseph P McGuirk, DO7, Moazzam Shahzad, MD8, Muhammad Umair Mushtaq, MD9
1 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
4 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
5 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
8 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
9 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States

Background:

Fludarabine-cyclophosphamide (FluCy) is the standard lymphodepletion regimen before chimeric antigen receptor (CAR) T-cell therapy; however, fludarabine shortages and concerns regarding toxicity have increased interest in bendamustine as an alternative. Comparative data on long-term survival, immune-mediated toxicities, infections, and hematologic recovery remain limited. We compared clinical outcomes after bendamustine- versus FluCy-based lymphodepletion after CD19 CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (LBCL).

Methods:

In this retrospective study, we analyzed patients with LBCL who received commercial CD19 CAR T-cell therapy (axicabtagene ciloleucel or tisagenlecleucel) from December 2017 through June 2022 after bendamustine- or FluCy-based lymphodepletion using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry (study P-6093). The primary endpoint was overall survival (OS). Secondary endpoints included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), day-100 infections, infection-related mortality, and neutrophil recovery. OS was estimated by Kaplan-Meier methods. Multivariable Cox models adjusted for age, HCT-CI, bridging therapy, and CAR T-cell product. Multivariable logistic models evaluated secondary outcomes. Propensity-based sensitivity analyses assessed robustness of survival findings. Statistical significance was defined as P<0.05.

Results:

Among 3,287 patients, 103 received bendamustine and 3,184 received FluCy. Patients in the bendamustine group were more often aged ≥65 years (52.4% vs 40.5%; P=0.020), more frequently received bridging therapy (35.0% vs 24.2%; P=0.019), had higher rates of complete or partial remission at infusion, and predominantly received tisagenlecleucel (89.3% vs 13.6%; P<0.001). Median follow-up was 25.4 months with bendamustine and 23.6 months with FluCy. OS did not differ significantly between groups. Twelve-month OS was 63.3% versus 63.7% and 24-month OS was 48.9% versus 49.3% for bendamustine and FluCy, respectively. Median OS was 21.6 versus 23.5 months (log-rank P=0.87). After multivariable adjustment, FluCy was not associated with OS compared with bendamustine (aHR 1.07, 95% CI 0.78–1.48; P=0.665), with consistent findings in propensity-based sensitivity analyses. FluCy was associated with higher odds of any-grade CRS (aOR 2.33, 95% CI 1.32–4.12; P=0.004), any-grade ICANS (aOR 3.02, 95% CI 1.16–7.87; P=0.023), and viral infection (aOR 3.56, 95% CI 1.14–11.11; P=0.028). Grade ≥2 CRS and ICANS, bacterial and fungal infections, and infection-related mortality did not differ significantly. Bendamustine was associated with delayed neutrophil recovery (HR 0.27, 95% CI 0.22–0.34; P<0.001). Tocilizumab use (aOR 2.03, P=0.048) and intravenous immunoglobulin replacement (aOR 8.11, P=0.004) were more common after FluCy.

Conclusions:

In this retrospective registry cohort, overall survival did not differ significantly between bendamustine- and FluCy-based lymphodepletion after CD19 CAR T-cell therapy for LBCL. FluCy was associated with higher odds of any-grade CRS, ICANS, and viral infection, whereas bendamustine was associated with delayed neutrophil recovery. Bendamustine may represent a reasonable alternative when fludarabine exposure is undesirable, although prospective validation and careful hematologic monitoring are warranted.

Muhammad Kashif Amin, MD, MSc, FACP: No relevant conflicts of interest to declare.